Table 1.
Demographic and clinical characteristics of human SLE subjects at the time peripheral blood was obtained.
| Age | Sex | PGA | SLEDAI | Flare | Main disease features | Previous medication |
|---|---|---|---|---|---|---|
| 27 | Female | 2.5 | 6 | Yes | Ulcer/arthritis/CNS/ANA+ | ΑΖΑ |
| 25 | Female | 3 | 18 | Yes | Rash/arthritis/renal/CNS/ANA+ | None |
| 65 | Female | 3 | 12 | No | Arthritis/ANA+/pericarditis | HCQ, AZA |
| 37 | Female | 1.5 | 10 | Yes | Rash/arthritis/CNS/ulcers/ANA+/alopecia/Hashimoto/peptic ulcer/asthma | None |
| 50 | Male | 2 | 0 | No | Rash/arthritis/CNS/ANA+/psoriasis/cataract | None |
| 38 | Female | 2.5 | 10 | No | Rash/arthritis/CNS/ulcers/ANA+/myositis/thrombophilia/lung nodules | ΜΤΧ, RTX, IVIg, IV-MP |
| 41 | Female | 0 | 6 | No | Ulcers/arthritis/ANA+/alopecia | ΜΤΧ |
| 51 | Female | 2 | 4 | No | Rash/arthritis/CNS/ANA+/alopecia/peptic ulcer | ΜΤΧ, ARAVA |
| 76 | Male | 3 | 3 | Yes | Rash/uclers/CNS/ANA+/haemolytic anaemia/thrombocytopenia/hypertension | CYC, IV-MP |
| 37 | Female | 1.5 | 7 | Yes | rash/arthritis/CNS/ulcers/Hashimoto/peptic ulcer/past | GI cancer none |
| 55 | Female | 1 | 6 | Yes | Rash/arthritis/CNS/ulcers/ANA+/alopecia | MTX |
| 43 | Female | 2 | 7 | Yes | Rash/arthritis/CNS/ANA+/Anti-DNA/Lung disease | None |
| 40 | Female | 1.5 | 6 | Yes | Rash/arthritis/CNS/ANA+ | ΜΤΧ |
| 74 | Female | 2 | 14 | No | Rash/arthritis/CNS/ANA+/anti-DNA/thyroiditis | None |
| 60 | Female | 1 | 0 | No | Rash/arthritis/CNS/ulcers/ANA+/renal/anti-DNA/APS | CYC, AZA, IV-MP |
| 40 | Female | 1 | 4 | No | Rash/arthritis/ulcers/CNS/ANA+/anti-DNA | MTX, DMSO, IV-MP |
| 38 | Female | 2.5 | 10+ | Yes | Arthritis/CNS/ulcers/ANA+/history of leukopenia/Hashimoto/lung nodules/thrombophilia | ΜΤΧ, RTX, IVIg, IV-MP |
| 74 | Female | 1.5 | 8+ | No | Rash/arthritis/CNS/ANA+/anti-DNA/thryroiditis | None |
| 32 | Female | 1 | 8 | No | Rash/ulcers/renal/CNS/arthritis/ANA+/thrombocytopenia/anti-DNA/thyroid disease | RTX |
| 36 | Female | 3 | 16 | No | Rash/ulcers/CNS/arthritis/ANA+/ | AZA |
| 38 | Female | 2 | 12 | No | Rash/ulcers/renal/CNS/arthritis/ANA+/alopecia/history of leukopenia | CYC, MMF |
| 52 | Female | 1 | 4 | Yes | Rash/ulcers/renal/CNS/arthritis/ANA+/alopecia/anti-DNA/APS | CYC, AZA, IV-MP |
| 41 | Female | 1 | 4 | No | Rash/ulcers/CNS/arthritis/ANA+/alopecia/Hashimoto/ | MTX |
| 58 | Female | 1.5 | 2 | No | Rash/CNS/arthritis/ANA+/history of leukopenia/anti-DNA/Hashimoto/ | HCQ, MTX, CYC, T4, Efexor, Bactrimel |
| 52 | Female | 2 | 4 | Yes | Rash/CNS/arthritis/ANA+/peptic ulcer | MTX, ARAVA |
| 48 | Female | 1 | 8 | No | Rash/ulcers/CNS/arthritis/alopecia/ANA+/hamelytic anaemia/leukopenia/anti-DNA | HCQ, MTX, AZA |
| 45 | Female | 1.5 | 6 | No | Rash/CNS/arthritis/ANA+/APS/cardiovascular disease | None |
| 64 | Female | 0.5 | 4 | No | Ulcers/CNS/arthritis/renal/ANA+/APS/Hashimoto/Sjögren's/ | CYC |
| 62 | Female | 0.5 | 4 | No | Ulcers/CNS/arthritis/ANA+ | MTX, CELESTONE |
| 53 | Female | 0.5 | 4 | No | Rash/CNS/arthritis/ANA+/thrombocytopenia/ | CYC, AZA, IV-MP |
| 49 | Female | 1.5 | 6 | No | Rash/ulcers/CNS/arthritis/renal/ANA+/Hashimoto | MTX/ARAVA |
| 47 | Female | 0.5 | 4 | Yes | Rash/arthritis/renal/CNS/ANA+/history of leukopenia/anaemia | None |
| 65 | Female | 2 | 8 | No | CNS/ANA+/history of leukopenia/thrombocytopenia/RA | CYC, AZA |
| 73 | Female | 1.5 | 6 | No | rash/CNS/arthritis/ANA+/alopecia/anti-DNA/cataract | CYC, AZA |
| 61 | Female | 2 | 6+ | No | CNS/arthritis/ANA+/alopecia/renal/PNS/diabetes/adrenal | HCQ, MTX, RTX |
| 60 | Female | 1.5 | 6 | Yes | Rash/CNS/arthritis/ANA+/alopecia/Hashimoto/diabetes | HCQ |
| 52 | Female | 1.5 | 14 | Yes | Rash/myelopathy/arthritis/CNS/ANA+/Hashimoto/cardiomyopathy | None |
| 29 | Male | 1.5 | 10 | Yes | Arthritis/rash/alopecia/history of leukopenia/fever/anaemia | None |
HCQ hydroxychloroquine, PZ prednisone, AZA azathioprine, MTX methotrexate, RTX rituximab, CYC cyclobenzaprine, IV-MP intravenous methylprednisolone, ARAVA Leflunomide, IVIg intravenous immunoglobulin, MMF Mycophenolate mofetil, DMSO dexamethasone, ANA anti-nuclear antibodies, CNS central nervous system, RA rheumatoid arthritis, PGA physician global assessment.